Staphylococcus Aureus Network Adaptive Platform Trial
SNAP
1 other identifier
interventional
8,000
13 countries
161
Brief Summary
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started Feb 2022
Longer than P75 for phase_4
161 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 25, 2021
CompletedFirst Posted
Study publicly available on registry
November 30, 2021
CompletedStudy Start
First participant enrolled
February 16, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2028
May 6, 2026
July 1, 2025
6.8 years
April 25, 2021
April 29, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
All-cause mortality at 90 days after platform entry
The primary endpoint for all cells and domains will be all-cause mortality at 90 days after platform entry. The primary endpoint will be determined through a search of hospital databases for a record of a participant's death, or follow-up contact with the participant's community healthcare provider, or follow-up contact with the patient or their nominated carer, or linkage with death registries.
From randomisation (day 1) until day 90
Secondary Outcomes (15)
Core1: All-cause mortality at 14, 28 and 42 days after platform entry
From randomisation (day 1) until day 14, 28, and 42
Core2: Duration of survival censored at 90 days after platform entry
From randomisation (day 1) until day 90
Core3: Length of stay of acute index inpatient hospitalisation for those surviving until discharge from acute inpatient facilities (excluding HITH/COPAT/OPAT/rehab).
From randomisation (day 1) until discharge from acute inpatient facilities, truncated at 90 days.
Core4: Length of stay of total index hospitalisation for those surviving until hospital discharge (including HITH/COPAT/OPAT/rehab)
From randomisation (day 1) to discharge from total index hospitalisation, truncated at 90 days
Core5: Time to being discharged alive from the total index hospitalisation (including HITH/COPAT/OPAT/rehab) truncated at 90 days after platform entry
From randomisation (day 1) to discharge from total index hospitalisation, truncated at 90 days
- +10 more secondary outcomes
Study Arms (12)
Methicillin-resistant staphylococcus aureus (MRSA) - Standard Therapy Arm (backbone therapy)
NO INTERVENTIONVancomycin or Daptomycin - Standard Therapy Arm Either intravenous vancomycin dosed as per Australian Therapeutic Guidelines: This includes a loading dose of 25 mg/kg (up to 3000mg) if considered appropriate by the treating clinician, initial maintenance dosing at 15-20 mg/kg q12h, with subsequent adjustment to maintain area under the concentration-time curve (AUC) of 400 to 600 mg.hr/L OR trough levels at 10-20 mg/L, and the initial level taken 48-72 hours after the initiation of the first dose. Daptomycin 8-10mg/kg per day intravenously. The choice of vancomycin or daptomycin will be at the clinician's discretion. Dosing will be based on renal function.
Methicillin-resistant staphylococcus aureus (MRSA) - Standard + B-Lactam Arm (backbone therapy)
EXPERIMENTALVancomycin or Daptomycin (Standard Therapy) + Beta-Lactam (β-lactam) Arm In addition to standard treatment an intravenous β-lactam will be added for the first 7 calendar days following randomisation (day 1 being the day of randomisation - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous cefazolin 2g every 8 hours. For patients with renal impairment the intravenous cefazolin administration doses will be adjusted.
Methicillin-susceptible staphylococcus aureus (MSSA) - Standard Therapy Arm (backbone therapy)
NO INTERVENTIONFlucloxacillin or cloxacillin - Standard Therapy Arm Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted.
Methicillin-susceptible staphylococcus aureus (MSSA) - Interventional Arm (backbone therapy)
EXPERIMENTALCefazolin - Interventional Arm Intravenous cefazolin 2g every 6 or 8 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous cefazolin administration dose will be adjusted.
Penicillin-susceptible staphylococcus aureus (PSSA) - Standard Therapy Arm (backbone therapy)
NO INTERVENTIONFlucloxacillin or cloxacillin - Standard Therapy Arm Either intravenous flucloxacillin/cloxacillin 2g every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with renal impairment or critical illness the intravenous flucloxacillin administration dose will be adjusted.
Penicillin-susceptible staphylococcus aureus (PSSA) - Interventional Arm (backbone therapy)
EXPERIMENTALBenzylpenicillin - Interventional Arm Intravenous benzylpenicillin 1.8g (3 million units) every 4 or 6 hours. The minimum protocol duration of allocated study treatment is 14 days for those not allocated to early oral switch, and 5 days for those allocated to early oral switch. For patients with critical illness the intravenous benzylpenicillin administration doses will be adjusted.
No adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm
NO INTERVENTIONNo adjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA Participants with either MRSA or MSSA or PSSA will have no adjunctive therapy in combination with their backbone therapy arm.
Adjunctive treatment in combination with MRSA or MSSA or PSSA backbone therapy arm
EXPERIMENTALAdjunctive therapy + backbone therapy arm for MRSA or MSSA or PSSA Intravenous clindamycin (or lincomycin) 600mg every 8 hours from platform day 1 to day 5. No dosage adjustment is needed to renal impairment.
Continue intravenous antibiotic therapies (backbone +/- adjunctive therapy) - standard of care arm
NO INTERVENTIONBackbone therapy arm for MRSA or MSSA or PSSA +/- adjunctive therapy will continue on intravenous antibiotic treatment for the length of time as per usual standard of care. Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised if not eligible then eligibility will be assess again at Day 14(+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain.
Switch to oral antibiotics at trial day 7 (+/- 2 days) or Day 14 (+/- 2 days) if eligible.
EXPERIMENTALSwitch from intravenous backbone antibiotic for MRSA or MSSA or PSSA to oral antibiotics at the treating clinicians discretion on trial Day 7 (+/- 2 days) or trial Day 14 (+/- 2 days). Participants eligibility is assessed at Day 7 (+/- 2 days). If eligible will be randomised, if not eligible then eligibility will be assessed again at Day 14 (+/- 2 days). If eligibility is not met at day 14 then participant is excluded from this domain.
No PET/CT scan - standard of care arm
NO INTERVENTIONParticipants will not receive a PET/CT scan, in addition to their allocated treatment interventions. Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised. If eligibility is not met then participant is excluded from this domain.
PET/CT scan at trial day 7 (+/- 2 days) if eligible
EXPERIMENTALParticipant will receive a PET/CT scan at Day 5-12, in addition to their allocated treatment interventions. Participants eligibility is assessed at Day 7 (+/- 2 days) if eligible will be randomised. If eligibility is not met then participant is excluded from this domain.
Interventions
Vancomycin or Daptomycin
Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.
This involves testing a strategy rather than individual antibiotic agents
Cefazolin
benzylpenicillin
Clindamycin
Eligibility Criteria
You may qualify if:
- Patients must fulfil all of the following criteria to be eligible to enter the SNAP trial:
- Staphylococcus aureus complex grown from ≥1 blood culture
- Admitted to a participating hospital at the time of eligibility assessment (OR if patient has died, they were admitted to this site anytime from the time of blood culture collection until the time of eligibility assessment)
You may not qualify if:
- Potentially eligible participants meeting any of the following criteria at the time of eligibility assessment for platform entry will be excluded from the randomised platform (but may still participate in the registry):
- Time of anticipated platform entry is greater than 72 hours post collection of the index blood culture (Where the time of culture collection is not recorded, the time of laboratory registration of the sample will be used as an alternative)
- Polymicrobial bacteraemia, defined as more than one organism (at species level) in the index blood cultures OR in any subsequent blood culture reported between the collection of the index blood culture and platform eligibility assessment, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician.
- Known previous participation in the randomised SNAP platform
- Known positive blood culture for S. aureus (of the same silo: PSSA, MSSA or MRSA) between 72 hours and 180 days prior to the time of eligibility assessment
- Treating team deems enrolment in the study is not in the best interest of the patient
- Treating team believes that death is imminent and inevitable
- Patient is for end-of-life care and antibiotic treatment is considered not appropriate
- Patient \<18 years of age and paediatric recruitment not approved at recruiting site
- Patient has died since the collection of the index blood culture
- To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)
- ADJUNCTIVE TREATMENT DOMAIN
- Patients are eligible for this domain regardless of S. aureus susceptibility testing results to clindamycin.
- \. Previous type 1 hypersensitivity reaction to lincosamides 2. Currently receiving clindamycin (lincomycin) or linezolid which cannot be ceased or substituted 3. Necrotising fasciitis 4. Current C. difficile associated diarrhoea (any severity) 5. Current severe diarrhoea from any cause (defined as Grade 3 or higher) 5. Known CDAD (C.Difficile Associated Diarrhoea) in the past 3 months, or CDAD relapse in the past 12 months 6. At the time of domain eligibility assessment, more than 4 hours has elapsed since platform entry 7. Treating clinician deems enrolment in this domain is not in the best interest of the patient
- PSSA, MSSA TREATMENT DOMAIN (backbone)
- +49 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Melbournelead
- Berry Consultantscollaborator
- Menzies School of Health Researchcollaborator
- Queensland University of Technologycollaborator
- Sunnybrook Health Sciences Centrecollaborator
- Tan Tock Seng Hospitalcollaborator
- Telethon Kids Institutecollaborator
- The University of Queenslandcollaborator
- UMC Utrechtcollaborator
- King's College Londoncollaborator
- Rambam Health Care Campuscollaborator
- McGill University Health Centre/Research Institute of the McGill University Health Centrecollaborator
- Aotearoa Clinical Trialscollaborator
- The Peter Doherty Institute for Infection and Immunitycollaborator
- Radboud University Medical Centercollaborator
- University College, Londoncollaborator
- The Methodist Hospital Research Institutecollaborator
Study Sites (161)
Houston Methodist Research Institute
Houston, Texas, 77030, United States
Canberra Hospital
Garran, Australia Capital Territory, 2605, Australia
Blacktown Hospital
Blacktown, New South Wales, 2148, Australia
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
Concord Repatriation and General Hospital
Concord, New South Wales, 2139, Australia
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
Nepean Hospital
Kingswood, New South Wales, 2747, Australia
St George Hospital
Kogarah, New South Wales, 2217, Australia
Liverpool Hospital
Liverpool, New South Wales, 2170, Australia
John Hunter Hospital
New Lambton Heights, New South Wales, 2305, Australia
John Hunter Children's Hospital
Newcastle, New South Wales, 2305, Australia
Orange Health Service
Orange, New South Wales, 2800, Australia
Prince of Wales Hospital
Randwick, New South Wales, 2031, Australia
Sydney Children's Hospital
Randwick, New South Wales, 2031, Australia
The Children's Hospital at Westmead
Westmead, New South Wales, 2145, Australia
Westmead Hospital
Westmead, New South Wales, 2145, Australia
Wollongong Hospital
Wollongong, New South Wales, 2500, Australia
Royal Darwin Hospital
Tiwi, Northern Territory, 0811, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, 4575, Australia
Cairns Hospital
Cairns, Queensland, 4870, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, 4029, Australia
Ipswich Hospital
Ipswich, Queensland, 4305, Australia
Logan Hospital
Meadowbrook, Queensland, 4131, Australia
Redcliffe Hospital
Redcliffe, Queensland, 4020, Australia
Robina Hospital
Robina, Queensland, 4226, Australia
Queensland Children's Hospital
South Brisbane, Queensland, 4101, Australia
Gold Coast University Hospital
Southport, Queensland, 4215, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
Lyell McEwin Hospital
Adelaide, South Australia, 5112, Australia
Flinders Medical Centre
Bedford Park, South Australia, 5042, Australia
Women and Children's Hospital
North Adelaide, South Australia, 5006, Australia
Women's and Children's Hospital
North Adelaide, South Australia, 5006, Australia
Royal Hobart Hospital
Hobart, Tasmania, 7000, Australia
Launceston Hospital
Launceston, Tasmania, 7250, Australia
Grampians Health
Ballarat, Victoria, 3350, Australia
Bendigo Health
Bendigo, Victoria, 3550, Australia
Box Hill Hospital
Box Hill, Victoria, 3128, Australia
Monash Children's Hospital
Clayton, Victoria, 3168, Australia
Monash Health - Monash Medical Centre & Jesse McPherson Private Hospital
Clayton, Victoria, 3168, Australia
Western Health - Footscray, Joan Kirner & Sunshine Hospitals
Footscray, Victoria, 3011, Australia
Frankston Hospital
Frankston, Victoria, 3199, Australia
Barwon Health - University Hospital Geelong
Geelong, Victoria, 3220, Australia
Austin Hospital
Heidelberg, Victoria, 3084, Australia
Alfred Hospital
Melbourne, Victoria, 3004, Australia
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
Royal Children's Hospital Melbourne
Parkville, Victoria, 3052, Australia
Goulburn Valley Health
Shepparton, Victoria, 3630, Australia
La Trobe Regional Hospital
Traralgon, Victoria, 3844, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, 6150, Australia
Perth Children's Hospital
Nedlands, Western Australia, 6009, Australia
Royal Perth Hospital
Perth, Western Australia, 6000, Australia
Armadale Hospital
Perth, Western Australia, 6112, Australia
Peter Lougheed Centre
Calgary, Alberta, T1Y 6J4, Canada
Foothills Medical Center
Calgary, Alberta, T2N4Z6, Canada
Rockyview Hospital
Calgary, Alberta, T2V 1P9, Canada
South Health Campus
Calgary, Alberta, T3M 1M4, Canada
University of Alberta Hospital
Edmonton, Alberta, T6G2B7, Canada
Richmond Hospital
Richmond, British Columbia, V6X1A2, Canada
Fraser Health Authority - Surrey Memorial Hospital
Surrey, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, V5Z1M9, Canada
St. Boniface Hospital
Winnipeg, Manitoba, R2H 2A6, Canada
Health Sciences Centre Winnipeg
Winnipeg, Manitoba, R3A1R9, Canada
Grace Hospital
Winnipeg, Manitoba, R3J 3M7, Canada
Eastern Health - Health Sciences Centre (Memorial University)
St. John's, Newfoundland and Labrador, A1B3V6, Canada
Eastern Regional Health Authority - St. Clare's Mercy Hospital
St. John's, Newfoundland and Labrador, Canada
Toronto East Health Network - Michael Garron Hospital
East York, Ontario, M4C3E7, Canada
University Health Network - Toronto General Hospital
East York, Ontario, M5G2C4, Canada
Hamilton Health Sciences - Hamilton General Hospital
Hamilton, Ontario, L8P1A2, Canada
Hamilton Health Sciences - Juravinski Hospital
Hamilton, Ontario, Canada
Kingston Health Sciences Centre - Kingston General Hospital
Kingston, Ontario, K7L2V7, Canada
London Health Sciences Centre - University Hospital, LHSC
London, Ontario, Canada
Niagara Health - Niagara Falls Site
Niagara Falls, Ontario, Canada
The Ottawa Hospital - Civic Campus
Ottawa, Ontario, K1H8L6, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Sault Area Hospital
Sault Ste. Marie, Ontario, P6B 0A8, Canada
Niagara Health - St. Catharines Site
St. Catharines, Ontario, L2S 0A9, Canada
Unity Health - St Michael's Hospital
Toronto, Ontario, M1L 1W1, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N3M5, Canada
Sinai Heath System - Mount Sinai Hospital
Toronto, Ontario, M5G1X5, Canada
Unity Health Toronto - St Joseph's Health Centre
Toronto, Ontario, Canada
University Health Network - Toronto Western Hospital
Toronto, Ontario, Canada
CISSS - Hôpital Cité-de-la-Santé Hospital
Laval, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, H3T1E2, Canada
McGill University Health Centre - Montral General Hospital
Montreal, Quebec, H4A3J1, Canada
McGill University Health Centre - Montreal Children's Hospital
Montreal, Quebec, Canada
McGill University Health Centre - Royal Victoria Hospital
Montreal, Quebec, Canada
HĂ´pital RĂ©gional de Saint JĂ©rĂ´me
Saint-JĂ©rĂ´me, Quebec, J7Z5T3, Canada
University of Sherbrooke Health Centre - Hospital Fleurimont
Sherbrooke, Quebec, J1H 5H3, Canada
University of Sherbrooke Health Centre - Hotel Dieu
Sherbrooke, Quebec, Canada
CHU de Rennes - HĂ´pital Pontchaillou
Rennes, France
Charité University Hospital Berlin
Berlin, Germany
University Hospital Carl Gustav Carus Dresden
Dresden, Germany
University Medical Centre Freiburg
Freiburg im Breisgau, Germany
Otto-von-Guericke-university Magdeburg
Magdeburg, Germany
Rambam Health Care Campus
Haifa, 310960, Israel
Beilinson Hospital
Petah Tikva, 49100, Israel
Schneider Hospital
Petah Tikva, Israel
Sheba Medical Centre
Ramat Gan, 49100, Israel
Science Tokyo University Hospital
Ichikawa, Chiba, 272-0827, Japan
Jeroen Bosch Hospital
's-Hertogenbosch, Netherlands
Rijnstate Hospital
Arnhem, Netherlands
Treant Ziekenhuis
Emmen, Netherlands
UMC Groningen
Groningen, Netherlands
Maastricht UMC+
Maastricht, Netherlands
Antonius Ziekenhuis
Nieuwegein, Netherlands
Radboud University Medical Center
Nijmegen, Netherlands
Ikazia Ziekenhuis
Rotterdam, Netherlands
University Medical Center Utrecht
Utrecht, Netherlands
Auckland City Hospital
Grafton, Auckland, 1023, New Zealand
Middlemore Hospital
Otahuhu, Auckland, 1640, New Zealand
North Shore Hospital
Takapuna, Auckland, 0620, New Zealand
Christchurch Hospital
Christchurch, Canterbury, 8011, New Zealand
Hutt Valley Hospital
Boulcott, Lower Hutt, 5010, New Zealand
Wellington Hospital
Newtown, Wellington Region, 6021, New Zealand
Starship Hospital
Auckland, 1023, New Zealand
KidzFirst
Auckland, 2025, New Zealand
Waikato Hospital
Hamilton, 3240, New Zealand
Tauranga Hospital
Tauranga, 3112, New Zealand
Whangarei Hospital
Whangarei, 0148, New Zealand
National University Hospital
Singapore, 119228, Singapore
Singapore General Hospital
Singapore, 168753, Singapore
Tan Tock Seng Hospital
Singapore, 308433, Singapore
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, South Africa
Helen Joseph Hospital
Johannesburg, South Africa
Rahima Moosa Mother and Child Hospital
Johannesburg, South Africa
Helsingborg Hospital
Helsingborg, Sweden
SUS Malmö
Malmö, Sweden
NHS Grampian
Aberdeen, United Kingdom
University Hospitals Birmingham
Birmingham, United Kingdom
Brighton and Sussex University Hospitals
Brighton, United Kingdom
North Bristol
Bristol, United Kingdom
University Hospitals Bristol and Weston
Bristol, United Kingdom
Cambridge University Hospitals
Cambridge, United Kingdom
Cardiff and Vale University
Cardiff, United Kingdom
Royal Cornwall Hospitals
Cornwall, United Kingdom
Royal Devon University Healthcare
Devon, United Kingdom
NHS Tayside
Dundee, United Kingdom
Lothian Western General
Edinburgh, United Kingdom
Greater Glasgow and Clyde
Glasgow, United Kingdom
NHS Golden Jubilee
Glasgow, United Kingdom
Hull University Teaching Hospitals
Hull, United Kingdom
Leeds Teaching Hospitals
Leeds, United Kingdom
Liverpool University Hospital
Liverpool, United Kingdom
Barts Health
London, United Kingdom
Great Ormond Street
London, United Kingdom
Guys and St Thomas'
London, United Kingdom
Imperial College Healthcare
London, United Kingdom
Kings College Hospital
London, United Kingdom
Royal Free London
London, United Kingdom
University College London Hospitals
London, United Kingdom
Whittington Health
London, United Kingdom
Manchester University Hospitals
Manchester, United Kingdom
Newcastle Upon Tyne Hospitals
Newcastle upon Tyne, United Kingdom
Nottingham University Hospitals
Nottingham, United Kingdom
Oxford University Hospitals
Oxford, United Kingdom
Sheffield Teaching Hospitals
Sheffield, United Kingdom
South Tees Hospitals
South Tees, United Kingdom
University Hospital Southampton
Southampton, United Kingdom
NHS Forth Valley
Stirling, United Kingdom
University Hospitals of North Midlands
Stoke, United Kingdom
Swansea Bay University Health Board
Swansea, United Kingdom
Related Publications (7)
Tong SYC, Mora J, Bowen AC, Cheng MP, Daneman N, Goodman AL, Heriot GS, Lee TC, Lewis RJ, Lye DC, Mahar RK, Marsh J, McGlothlin A, McQuilten Z, Morpeth SC, Paterson DL, Price DJ, Roberts JA, Robinson JO, van Hal SJ, Walls G, Webb SA, Whiteway L, Yahav D, Davis JS; Staphylococcus aureus Network Adaptive Platform (SNAP) Study Group. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. Clin Infect Dis. 2022 Nov 30;75(11):2027-2034. doi: 10.1093/cid/ciac476.
PMID: 35717634BACKGROUNDSymons TJ, Straiton N, Gagnon R, Littleford R, Campbell AJ, Bowen AC, Stewart AG, Tong SYC, Davis JS. Consumer perspectives on simplified, layered consent for a low risk, but complex pragmatic trial. Trials. 2022 Dec 28;23(1):1055. doi: 10.1186/s13063-022-07023-z.
PMID: 36578070BACKGROUNDMalhame I, Hardy E, Cheng MP, Tong SY, Bowen AC. Walking the walk to include pregnant participants in non-obstetric clinical trials: Insights from the SNAP Trial. Obstet Med. 2023 Mar;16(1):3-4. doi: 10.1177/1753495X231163351. Epub 2023 Mar 22. No abstract available.
PMID: 37139509BACKGROUNDHenderson A, Cheng MP, Chew KL, Coombs GW, Davis JS, Grant JM, Gregson D, Giulieri SG, Howden BP, Lee TC, Nguyen V, Mora JM, Morpeth SC, Robinson JO, Tong SYC, Van Hal SJ; Microbiology Working Group of the Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group. A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus. J Antimicrob Chemother. 2023 Jun 1;78(6):1499-1504. doi: 10.1093/jac/dkad116.
PMID: 37071589BACKGROUNDde Kretser D, Mora J, Bloomfield M, Campbell A, Cheng MP, Guy S, Hensgens M, Kalimuddin S, Lee TC, Legg A, Mahar RK, Marks M, Marsh J, McGlothin A, Morpeth SC, Sud A, Ten Oever J, Yahav D, Bonten M, Bowen AC, Daneman N, van Hal SJ, Heriot GS, Lewis RJ, Lye DC, McQuilten Z, Paterson DL, Owen Robinson J, Roberts JA, Scarborough M, Webb SA, Whiteway L, Tong SYC, Davis JS, Walls G, Goodman AL; SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee; SNAP Trial Group. Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clin Infect Dis. 2024 Oct 15;79(4):871-887. doi: 10.1093/cid/ciad666.
PMID: 37921609BACKGROUNDMahar RK, McGlothlin A, Dymock M, Lee TC, Lewis RJ, Lumley T, Mora J, Price DJ, Saville BR, Snelling T, Turner R, Webb SA, Davis JS, Tong SYC, Marsh JA; SNAP Global Trial Steering Committee. A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2023 Dec 6;24(1):795. doi: 10.1186/s13063-023-07718-x.
PMID: 38057927BACKGROUNDMahar RK, McGlothlin A, Dymock M, Barina L, Bonten M, Bowen A, Cheng MP, Daneman N, Goodman AL, Lee TC, Lewis RJ, Lumley T, McLean ARD, McQuilten Z, Mora J, Paterson DL, Price DJ, Roberts J, Snelling T, Tverring J, Webb SA, Yahav D, Davis JS, Tong SYC, Marsh JA; SNAP Global Trial Steering Committee. Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2025 Feb 11;26(1):49. doi: 10.1186/s13063-024-08684-8.
PMID: 39934879DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Prof Steven Tong
University of Melbourne / Melbourne Health
- STUDY CHAIR
Prof Joshua Davies
Menzies School of Research / Hunter New England Medical Centre
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- This is an open-label study
- Purpose
- TREATMENT
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 25, 2021
First Posted
November 30, 2021
Study Start
February 16, 2022
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
December 1, 2028
Last Updated
May 6, 2026
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
- Time Frame
- IPD and supporting information will be available 12 months after the publication of the primary results manuscript and will be available for a 10 year period.
- Access Criteria
- • All requests for data sharing must be accompanied by a SNAP data access request from, a study proposal with clear statement of aims and hypotheses, and a statistical analysis plan. All applications will be assessed by the SNAP Trial Steering Committee. Applications from investigators with suitable academic capability to conduct the proposed work will be given consideration. If a proposal is approved, a signed data transfer agreement will be required before data sharing.
De-identified patient data